Bivalirudin reduces bleeding rate in carotid stenting

Courtesy of Dr. Carlos Fava

bivalirudina-heparina-anticoagulantesBivalirudin has been shown to reduce bleeding in carotid stenting and maintain its efficacy. Even though carotid stenting has shown benefits, these remain unclear.

 

With this in mind, four studies were analyzed (one randomized) including 7,784 patients undergoing carotid stenting with unfractioned heparin vs. bivalirudin.

 

No difference was found between the groups across the different studies.

 

Bivalirudin was shown to reduce major bleeding rate with a relative risk (RR) of 0.53 (95% CI: 0.35-0.8; I2=0%) and minor bleeding RR of 0.41 (95% CI: 0.2-0.82; I2 =0%), with no difference in ischemic stroke, intracranial bleeding, infraction or mortality at 30 days.

 

Conclusion

Compared to unfractioned heparin, bivalirudin was associated with lower bleeding risk when used in carotid stenting.

 

Comment

The use of bivalirudin has shown this benefit in coronary PCI, but the transradial approach has also shown this benefit in PCI with unfractioned heparin.

 

In addition, bivalirudin significantly increases costs compared to unfractioned heparin.

 

Perhaps the use of the transradial approach (which several studies show as feasible and safe) neutralizes this benefit of bivalirudin, except for those cases that, for several reasons, should be done via femoral.  

 

Courtesy of Dr. Carlos Fava

 

Original Title: Hemorrhagic and Ischemic Outcomes of Heparin vs. Bivalirudin in Carotid Artery Stenting: A Meta-analysis of Studies.

Reference: Jad Omran, et; al. Catheterization and Cardiovascular Intervention 2017;88:746-753.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...